Yisheng Biopharma Co Ltd
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Yisheng Biopharma Co Ltd
Adjuvant Capital believes its fund will ultimately lead to greater access to medical advances in low-income countries while making a healthy return for its high-profile investors.
Silicos NV's computational lead identification and development platform combines proprietary and commercial computational chemistry tools, and has potential in many indications such as cancer and infectious diseases, central nervous system disorders, and immunodeficiency diseases. The company is using its virtual fragment-based tools to create small molecules for both clients and for its own internal projects.
Summarizing the month in European dealmaking.
Cenix is equipped to do high-throughput, genome-scale RNAi screening. The firm believes that its infrastructure and expertise will allow it to help Big pharma and biotech partners sort through masses of targets to find those with biological relevance. Management believes its methodology can also contribute to drug development--RNAi could, for instance, act as a modifier in screening assays, to see whether this additional means of silencing a gene could improve a drug candidate's activity.
- Other Names / Subsidiaries
- Yisheng US Biopharma, Inc.